ALK – Finanskalender for regnskabsåret 2024
20 déc. 2023 04h45 HE
|
ALK Abello
Finanskalender 2024 for ALK (ALKB:DC / OMX: ALK B / AKBLF): 11. januar 2024: Stilleperiode8. februar 2024: Offentliggørelse af årsrapport 202314. marts 2024 kl. 16.00: Ordinær generalforsamling...
ALK – Financial calendar for the 2024 financial year
20 déc. 2023 04h45 HE
|
ALK Abello
2024 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 11 January 2024: Silent period 8 February 2024: Annual report 2023 14 March 2024 at 4.00 p.m.: Annual...
ALK udvider partnerskab med Torii i Japan
12 déc. 2023 10h08 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) og selskabets japanske partner Torii Pharmaceutical Co., Ltd. (’Torii’) meddeler i dag, at de har udvidet samarbejdet og har indgået yderligere en licensaftale, der...
ALK expands partnership with Torii in Japan
12 déc. 2023 10h08 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) and its Japanese partner Torii Pharmaceutical Co., Ltd. ('Torii') today announced that they have expanded their collaboration and entered into an additional license...
Nine-month interim report (Q3) 2023
15 nov. 2023 01h30 HE
|
ALK Abello
Bemærk venligst, at rapporten udelukkende forefindes på engelsk ALK delivers 8% revenue growth with operating profit up 128% in Q3 (unaudited) ALK saw growth in all sales regions in Q3, led...
Nine-month interim report (Q3) 2023
15 nov. 2023 01h30 HE
|
ALK Abello
ALK delivers 8% revenue growth with operating profit up 128% in Q3 (unaudited) ALK saw growth in all sales regions in Q3, led by sales of tablets and SCIT. As expected, European tablet sales...
Dato for offentliggørelse af delårsrapport for første ni måneder (Q3) 2023 for ALK og webcast
09 nov. 2023 07h46 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør delårsrapport for første ni måneder (Q3) 2023 onsdag den 15. november 2023. ALK afholder samme dag kl. 13.30 (CET) en telekonference for investorer...
Release date of nine-month interim report (Q3) 2023 for ALK and audio cast
09 nov. 2023 07h46 HE
|
ALK Abello
On Wednesday, 15 November 2023 ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its nine-month interim report (Q3) 2023. ALK will host a meeting for analysts and institutional investors that day at 1.30pm...
Stort klinisk fase 3-studie når sit primære endemål og bekræfter potentialet af ALK’s tabletvaccine mod træpollenallergi til børn
11 oct. 2023 10h13 HE
|
ALK Abello
Fase 3 effekt- og sikkerhedsstudiet med ALK’s tabletvaccine mod træpollenallergi omfattede 952 børn i alderen 5 til 17 år i Canada og EuropaALK har nu succesfuldt fuldført den kliniske udvikling af...
Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s tree tablet in children
11 oct. 2023 10h13 HE
|
ALK Abello
The Phase 3 efficacy and safety trial of ALK’s tree tablet involved 952 children aged 5 to 17 in Canada and Europe.ALK has now successfully completed pivotal clinical development for all five...